PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ascentage Pharma

Ascentage Pharma Obtains an Option Payment of $100M from Takeda

Ascentage Pharma Obtains an Option Payment of $100M from Takeda

July 4, 2024

Ascentage Pharma Reports the US FDA’s Clearance to Commence the P-III Study of Olverembatinib for Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Reports the US FDA’s Clearance to Commence the P-III Study of Olverembatinib for Chronic-Phase Chronic Myeloid Le...

February 14, 2024

Ascentage Pharma Entered into Clinical Collaboration with AstraZeneca for Lisaftoclax + Acalabrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Ascentage Pharma Entered into Clinical Collaboration with AstraZeneca for Lisaftoclax + Acalabrutinib in Chronic Lymphocytic Leuke...

October 17, 2023

Ascentage Pharma to Present P-II Study Results of Lisaftoclax (APG-2575) for Chronic Lymphocytic Leukemia at ASH 2022

Ascentage Pharma to Present P-II Study Results of Lisaftoclax (APG-2575) for Chronic Lymphocytic Leukemia at ASH 2022

November 4, 2022

Ascentage Pharma's Alrizomadlin (APG-115) Receives the US FDA’s Rare Pediatric Disease Designation for the Treatment of Neuroblastoma

Ascentage Pharma's Alrizomadlin (APG-115) Receives the US FDA’s Rare Pediatric Disease Designation for the Treatment of Neuroblast...

March 22, 2022

Ascentage Pharma Entered into a Clinical Collaboration with Clover to Evaluate APG-1387 + SCB-313 for the Treatment of Peritoneal Carcinomatosis

Ascentage Pharma Entered into a Clinical Collaboration with Clover to Evaluate APG-1387 + SCB-313 for the Treatment of Peritoneal...

December 10, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us